Key Highlights
- Third quarter loss per share was USD 0.72 against an estimated USD 0.64 loss, with no Revenue reported.
- Cash, equivalents and marketable securities were USD 249.8 million, and nine-month net loss reached USD 89.1 million.
- A workforce reduction of about 46% was announced in September to focus resources on the dual combination program.
- The AscenSION CF Phase 2 proof-of-concept trial is scheduled to begin in the first quarter of 2027.
Sionna Therapeutics (NASDAQ:SION), a clinical-stage company developing treatments for cystic fibrosis, reported a third quarter 2026 loss of USD 0.72 per share, wider than the USD 0.64 estimate. The company reported no revenue. Net loss for the first nine months was USD 89.1 million, compared with USD 54.8 million a year earlier.
Research and development expenses rose USD 6.0 million to USD 22.0 million in the quarter. For the nine months they rose USD 17.8 million to USD 62.9 million. Interest income fell USD 1.0 million to USD 2.4 million on lower average Investment balances. The accumulated Deficit was USD 345.4 million.
In August 2026 the company announced topline results from the PreciSION CF Phase 2a trial of a separate NBD1 stabilizer tested as an add-on to Trikafta. Following that development, in September it announced a workforce reduction of approximately 46% and other cost-saving measures intended to focus resources on the dual combination program and extend its operating runway.
The company also reported a post hoc analysis of PreciSION CF. Its filing states that management believes the analyses suggest that candidate was biologically active, but that confounding factors may have affected the observed outcome and blunted a potential treatment signal. These are the company's own interpretations of a trial that did not meet its goals as originally designed.
The Dual Combination Program
Also in August, the company announced topline results from a Phase 1 trial of an NBD1 stabilizer in dual combinations with each of two complementary modulator candidates. Based on clinical, pharmacokinetic and nonclinical data, it selected one NBD1 stabilizer paired with one of the modulators.
The AscenSION CF Phase 2 proof-of-concept trial is scheduled to begin in the first quarter of 2027. It is an open-label trial in people with cystic fibrosis who switch from the current standard of care, Vertex Pharmaceuticals' Trikafta, to the dual combination for 28 days.
Funding and Liquidity
Cash, cash equivalents and marketable securities were USD 249.8 million at September 30. Since inception the company has raised aggregate net proceeds of USD 530.0 million from preferred stock sales and its initial public offering. In March 2026 it entered a sales agreement with Leerink Partners for an at-the-market program with up to USD 250.0 million in aggregate gross proceeds.
Net cash used in Operating Activities for the nine months ended September 30, 2025 was USD 49.7 million, and financing inflows in that period were USD 204.1 million as the initial public offering closed.
The filing's legal proceedings section states that management is not currently aware of any legal matters that could have a material effect on the company's financial position, results of operations or cash flows.
Markers for the Coming Quarters
The start of the AscenSION CF trial, the effect of the smaller workforce on quarterly spending, and the balance of cash against that spending are the items to follow. Updates on how the company interprets the PreciSION CF data may also appear in later filings.






Please wait processing your request...